background
autophagi
report
play
pivot
role
replic
variou
rna
virus
studi
investig
role
autophagi
hepat
c
viru
hcv
rna
replic
demonstr
antihcv
effect
autophag
proteolysi
inhibitor
chloroquin
method
induct
autophagi
evalu
follow
transfect
hcv
replicon
cell
next
investig
replic
hcv
subgenom
replicon
respons
treatment
lysosom
proteas
inhibitor
pharmacolog
autophagi
inhibitor
effect
hcv
replic
analyz
transfect
sirna
lightchain
lc
replicon
cell
antivir
effect
chloroquin
andor
interferona
ifna
evalu
result
transfect
hcv
replicon
increas
number
autophagosom
twofold
untransfect
cell
pharmacolog
inhibit
autophag
proteolysi
significantli
suppress
express
level
hcv
replicon
silenc
autophagyrel
gene
sirna
transfect
significantli
blunt
replic
hcv
replicon
treatment
replicon
cell
chloroquin
suppress
replic
hcv
replicon
dosedepend
manner
furthermor
combin
treatment
chloroquin
ifna
enhanc
antivir
effect
ifna
prevent
repropag
hcv
replicon
protein
kinas
r
activ
cell
treat
ifna
chloroquin
incub
chloroquin
decreas
degrad
longliv
protein
leucin
conclus
result
studi
suggest
replic
hcv
replicon
util
machineri
involv
cellular
autophag
proteolysi
therapi
target
autophag
proteolysi
use
chloroquin
may
provid
new
therapeut
option
chronic
hepat
c
genom
hcv
member
famili
flavivirida
consist
positivesens
singlestrand
rna
peginterferonribavirin
combin
therapi
effect
therapi
hcv
infect
effect
around
genotyp
genotyp
howev
mani
peopl
toler
seriou
side
effect
resist
peginterferonribavirin
combin
therapi
difficulti
erad
hcv
attribut
limit
number
treatment
option
hcv
therefor
search
novel
therapeut
agent
remain
strong
aspir
autophagi
evolutionarili
conserv
cellular
pathway
cytoplasm
organel
engulf
within
doublemembran
vesicl
known
autophagosom
cellular
autophagi
thought
prepar
turnov
recycl
cellular
constitu
process
propos
mechan
viru
replic
complex
format
positivestrand
rna
virus
includ
polioviru
equin
arter
viru
coronaviru
virus
replic
complex
consist
doubl
membran
vesicl
cytoplasm
suggest
autophagosom
origin
recent
report
transfect
hcv
replicon
induc
autophagi
addit
sir
et
al
demonstr
suppress
autophagi
inhibit
replic
hcv
find
suggest
autophagi
play
pivot
role
hcv
replic
chloroquin
wide
use
treatment
malaria
wellestablish
inhibitor
autophag
proteolysi
act
inhibit
acidif
lysosom
endosom
report
chloroquin
exert
direct
antivir
effect
sever
rna
virus
includ
coronavirus
flavivirus
human
immunodefici
viru
hiv
moreov
clinic
studi
demonstr
safeti
toler
efficaci
chloroquin
antivir
treatment
hiv
infect
demonstr
autophag
proteolysi
play
pivot
role
hcv
replic
moreov
inhibit
autophag
proteolyt
pathway
constitut
effect
new
therapeut
target
hcv
cell
cultur
treatment
cell
stabli
transfect
hcv
replicon
express
chimer
protein
firefli
luciferas
neomycin
phosphotransferas
cultur
dulbecco
modifi
essenti
medium
dmem
sigma
st
loui
mo
supplement
foetal
bovin
serum
fb
co
maintain
cell
line
carri
hcv
replicon
wako
osaka
japan
ad
medium
final
concentr
lgml
luciferas
activ
quantifi
evalu
replic
hcv
replicon
luminomet
lumat
berthold
germani
use
brightglo
luciferas
assay
system
promega
madison
wi
assay
perform
triplic
result
express
mean
sd
percent
control
viabil
cell
assess
assay
cell
cultur
plate
well
h
treat
mm
mixtur
lgml
pepstatin
lgml
chloroquin
h
cell
prolifer
reagent
roch
swiss
ad
well
cell
incub
anoth
h
absorb
measur
background
control
micropl
reader
spectra
max
molecular
devic
sunnyval
ca
nm
refer
wavelength
nm
inhibit
autophagi
replic
hcv
replicon
cell
treat
mm
mixtur
lgml
pepstatin
lgml
chloroquin
interferon
ifn
uml
h
level
replic
hcv
replicon
assess
luciferas
assay
moreov
cell
cultur
chloroquin
andor
ifna
uml
day
continu
incub
without
drug
anoth
day
replic
level
hcv
replicon
determin
luciferas
assay
day
cessat
drug
cell
cell
treat
ifna
day
seed
mm
dish
incub
h
addit
cell
treat
chloroquin
h
cell
prefix
glutaraldehyd
postfix
osmic
acid
dehydr
grade
ethanol
embed
resin
cut
section
ultramicrotom
cell
analyz
transmiss
electron
microscop
hitachi
japan
number
autolysosom
lm
cytoplasm
count
use
transmiss
electron
microscopi
small
interf
rna
knockdown
combin
four
chemic
synthes
sirna
duplex
molecul
target
human
mrna
sequenc
dharmacon
lafayett
co
transient
transfect
final
concentr
nm
cell
use
transfect
reagent
dharmacon
lafayett
co
sirna
target
enhanc
green
fluoresc
protein
use
control
fortyeight
hour
transfect
level
hcv
replic
analyz
luciferas
assay
twentyf
microgram
total
cell
lysat
subject
sdspage
gradient
gel
electrophoret
transfer
onto
polyvinyliden
fluorid
membran
block
nonfat
dri
milk
trisbuff
salin
membran
incub
primari
rabbit
monoclon
antibodi
phosphoprotein
kinas
r
ppkr
cell
signal
technolog
danver
lightchain
follow
secondari
horseradish
peroxidas
hrp
conjug
antirabbit
igg
antibodi
cell
signal
technolog
danver
subsequ
specif
band
visual
use
ecl
detect
kit
amersham
pharmacia
biotech
midland
canada
long
live
protein
mainli
degrad
autophagi
cell
incub
william
fb
contain
lciml
c
leucin
h
label
longliv
protein
cell
wash
william
fb
contain
unlabel
leucin
incub
medium
h
allow
degrad
shortliv
protein
minim
incorpor
label
leucin
cell
wash
phosphatebuff
salin
pb
incub
william
fb
presenc
absenc
chloroquin
h
aliquot
medium
taken
onetenth
volum
trichloroacet
acid
ad
aliquot
mixtur
centrifug
min
acidsolubl
radioact
determin
use
liquid
scintil
counter
end
experi
cultur
wash
twice
pb
ml
cold
trichloroacet
acid
ad
fix
cell
protein
fix
cell
monolay
wash
trichloroacet
acid
dissolv
ml
n
naoh
radioact
aliquot
n
naoh
determin
liquid
scintil
count
percentag
protein
degrad
calcul
accord
publish
procedur
differ
compar
use
anova
basic
p
valu
less
consid
statist
signific
count
number
autophagosom
autolysosom
cell
transduc
hcv
replicon
repfeo
use
electron
microscopi
doubl
membran
vesicl
morpholog
autophagosom
identifi
vacuolescel
cell
transfect
hcv
replicon
increas
number
vacuol
fourfold
untransfect
cell
fig
b
subsequ
treatment
cell
ifna
uml
day
elimin
hcv
replicon
substanti
decreas
autophagolysosom
cytoplasm
cell
fig
b
observ
suggest
hcv
replicon
induc
format
autophagosom
clarifi
role
autophagi
replic
hcv
repfeo
cell
treat
mm
mixtur
lgml
pepstatin
lgml
inhibit
autophag
protein
degrad
replic
level
hcv
replicon
cell
increas
twofold
h
control
media
howev
incub
complet
blunt
increas
replic
hcv
replicon
treatment
decreas
number
autophagosom
cell
furthermor
coincub
pepstatin
decreas
replic
hcv
replicon
control
fig
next
assay
perform
check
cytotox
drug
treatment
mixtur
fig
inhibit
autophagi
suppress
replic
hcv
replicon
cell
treat
mm
mixtur
lgml
pepstatin
pep
lgml
h
level
replic
hcv
replicon
assess
luciferas
assay
b
cell
treat
mm
mixtur
lgml
pepstatin
lgml
h
cell
prolifer
reagent
ad
well
cell
incub
hour
absorb
measur
background
control
micropl
reader
nm
refer
wavelength
nm
c
combin
four
chemic
synthes
sirna
duplex
molecul
target
human
mrna
sequenc
transient
transfect
cell
use
transfect
reagent
sirna
target
enhanc
green
fluoresc
protein
use
control
fortyeight
hour
transfect
level
hcv
replic
analyz
luciferas
assay
pepstatin
affect
cell
viabil
fig
clarifi
role
autophagi
induct
replic
hcv
suppress
induct
autophagi
silenc
autophagyrel
gene
sirna
transfect
silenc
autophagyrel
gene
reduc
replic
hcv
replicon
control
fig
transfect
sirna
autophagi
relat
gene
decreas
number
autophagosom
control
result
indic
autophagi
play
pivot
role
replic
hcv
chloroquin
inhibit
replic
hcv
replicon
next
evalu
antihcv
effect
chloroquin
lysosomotrop
agent
rais
intralysosom
ph
impair
autophag
protein
degrad
assess
effect
chloroquin
intracellular
replic
hcv
replicon
cell
cultur
variou
concentr
chloroquin
medium
replic
hcv
replicon
increas
twofold
within
h
control
media
howev
suppress
chloroquin
dosedepend
manner
fig
next
cytotox
chloroquin
analys
assay
cell
treat
chloroquin
show
signific
effect
cell
viabil
dose
lower
fig
howev
incub
chloroquin
reduc
cell
viabil
control
basi
toxic
curv
ic
drug
calcul
fig
averag
ec
chloroquin
calcul
fig
replic
hcv
replicon
suppress
nearli
control
chloroquin
affect
cell
viabil
data
indic
chloroquin
effici
inhibit
replic
hcv
replicon
absenc
toxic
effect
cell
concentr
accordingli
use
chloroquin
follow
studi
next
conduct
follow
assay
determin
synergist
inhibitori
effect
chloroquin
ifna
hcv
replic
treatment
chloroquin
h
c
calcul
ec
ic
concentr
chloroquin
inhibit
replic
hcv
replicon
show
ec
ic
concentr
chloroquin
inhibit
cell
prolifer
repfeo
cell
result
signific
decreas
hcv
replicon
control
hand
incub
ifna
h
inhibit
replic
hcv
replicon
level
control
expect
howev
coincub
ifna
chloroquin
decreas
hcv
replic
significantli
fig
determin
whether
longterm
chloroquin
treatment
inhibit
posttreat
repropag
hcv
replicon
follow
luciferas
activ
cell
day
day
treatment
chloroquin
andor
ifna
fig
hcv
replicon
cell
treat
chloroquin
luciferas
activ
recov
day
cessat
treatment
cell
treat
ifna
luciferas
activ
maintain
background
level
day
posttreat
howev
reappear
day
sharp
contrast
coincub
ifna
chloroquin
day
suppress
hcv
replic
extens
period
day
even
absenc
drug
fig
antihcv
effect
chloroquin
independ
ifn
signal
pathway
ifninduc
doublestrand
rnaactiv
protein
kinas
r
pkr
play
key
antivir
role
hepat
c
viru
elucid
mechan
inhibitori
effect
chloroquin
hcv
replic
phosphoryl
pkr
ppkr
evalu
western
blot
analysi
ppkr
detect
cell
treat
ifna
h
increas
ppkr
express
peak
h
ifna
treatment
reduc
h
fig
contrast
ppkr
observ
cell
treat
chloroquin
time
point
report
chloroquin
disrupt
lysosom
function
prevent
effect
autophag
protein
degrad
lead
accumul
ineffect
autophagosom
therefor
investig
chloroquin
led
accumul
autolysosom
result
suppress
proteolysi
perform
electron
microscop
investig
evalu
quantiti
autophagosom
autolysosom
ultrastructur
analysi
identifi
lm
autolysosom
control
cell
howev
treatment
chloroquin
increas
number
autolysosom
dramat
control
fig
furthermor
molecular
form
protein
cell
compon
autophagosom
examin
western
blot
analysi
ensur
chloroquin
treatment
lead
accumul
autophagosom
autolysosom
shown
fig
immunoposit
protein
band
form
clearli
evid
control
cell
chloroquin
treatment
express
increas
h
fig
threefold
control
without
enhanc
express
h
fig
express
enhanc
final
evalu
turnov
longliv
protein
leucin
mainli
degrad
autophagi
cell
label
c
leucin
h
degrad
c
leucin
cell
treat
without
chloroquin
measur
chloroquin
treatment
decreas
degrad
leucin
control
indic
chloroquin
blunt
degrad
protein
via
autophag
b
assess
repropag
hcv
replicon
long
term
treatment
chloroquin
andor
ifna
repfeo
incub
chloroquin
andor
ifna
uml
day
drug
remov
medium
incub
continu
anoth
day
luciferas
assay
perform
day
cessat
drug
valu
shown
percentag
control
cell
p
vs
ifna
treatment
group
day
anova
pathway
fig
result
demonstr
chloroquineinduc
accumul
autolysosom
due
disrupt
autophag
proteolysi
previou
report
disclos
autophagi
play
pivot
role
replic
sever
rna
virus
present
result
demonstr
autophagi
induc
transfect
hcv
replicon
reduc
delet
replicon
due
ifna
fig
b
result
suggest
autophagi
induc
presenc
hcv
replic
host
cell
howev
role
autophagi
pathogenesi
hcv
larg
unclear
found
inhibit
autophagosom
format
autophag
proteolysi
blunt
replic
genotyp
subgenom
hcv
replicon
fig
c
sir
et
al
report
inhibit
autophagi
also
reduc
replic
full
length
genotyp
genom
therefor
util
autophagi
viral
replic
shown
hcv
strain
across
differ
genotyp
hand
silenc
autophag
gene
also
pharmacolog
inhibit
autophag
proteolysi
possess
antihcv
effect
fig
c
howev
treatment
chloroquin
mixtur
pepstatin
induc
accumul
autophagosom
cytoplasm
therefor
like
hcv
util
doubl
membran
structur
local
viral
replic
format
result
support
hypothesi
protein
degrad
due
autophagi
import
hcv
replic
chloroquin
wellknown
inhibitor
autophag
protein
degrad
often
use
antimalari
agent
moreov
antivir
effect
chloroquin
rna
virus
alreadi
report
clinic
trial
result
chloroquin
inhibit
intracellular
replic
hcv
replicon
dosedepend
manner
fig
antivir
effect
chloroquin
clearli
due
cytotox
effect
fig
moreov
chloroquin
possess
synergist
effect
ifna
hcv
replic
fig
although
ifna
possess
strong
antihcv
effect
repropag
hcv
replicon
observ
week
follow
day
treatment
ifna
interestingli
coincub
ifna
chloroquin
day
prevent
repropag
hcv
replicon
fig
chloroquin
lysosom
weak
base
known
affect
acid
vesicl
lead
dysfunct
sever
protein
demonstr
disrupt
lysosom
function
impair
matur
virus
inhibit
lowph
depend
proteas
transgolgi
vesicl
hiv
sar
coronaviru
infect
vitro
howev
littl
understood
mechan
antivir
effect
previou
report
variou
drug
possess
inhibitori
effect
replic
hcv
synergist
action
ifna
propos
new
therapeut
agent
treat
hcv
prove
exhibit
antihcv
effect
augment
ifninduc
antivir
gene
respons
howev
antihcv
effect
chloroquin
associ
activ
one
ifn
receptor
signal
molecul
pkr
fig
result
show
chloroquin
induc
accumul
ineffect
autophagosom
cytoplasm
cell
fig
inhibit
degrad
longliv
protein
leucin
fig
find
impli
chloroquin
effect
impair
function
autophagi
experi
result
indic
chloroquin
new
antihcv
agent
target
autophag
proteolysi
previou
report
shown
chloroquin
possess
antivir
effect
variou
rna
virus
beststudi
effect
hiv
replic
test
clinic
trial
hcv
coinfect
common
hivposit
patient
usa
europ
sinc
hiv
infect
acceler
progress
hcvrelat
liver
diseas
treatment
hcv
gener
recommend
howev
coinfect
patient
greater
risk
antiretrovir
therapyassoci
hepatotox
patient
hiv
moreov
treatment
ribavirin
believ
increas
risk
anemia
patient
take
hiv
drug
zidovudin
clinic
studi
design
hiv
patient
show
safeti
efficaci
chloroquin
use
long
term
week
therefor
combin
therapi
interferon
chloroquin
possibl
hope
therapi
hcvhiv
coinfect
patient
sinc
chloroquin
known
one
inexpens
drug
therefor
chloroquin
might
provid
new
effect
safe
econom
therapeut
option
patient
hcv
conclus
autophag
proteolysi
might
new
therapeut
target
replic
hcv
